140646-80-6

140646-80-6 structure

Name	MCI826
Synonyms	2,2-Diethyl-4-({3-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)vinyl]phenyl}amino)-4-oxobutanoic acid Butanoic acid, 2,2-diethyl-4-[[3-[(E)-2-[4-(1-methylethyl)-2-thiazolyl]ethenyl]phenyl]amino]-4-oxo-

Description	MCI826 is a P-glycoprotein (P-gp) antagonist.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein Research Areas >> Cancer
Target	P-glycoprotein[1]
In Vitro	Verapamil and cyclosporine A, first-generation modulators, and MCI826 (VX-710), a third generation P-gp modulator, are effective enhancers of C6-ceramide response in cells. Verapamil and MCI826 demonstrate weak cytotoxicity alone; however, when administered with C6-ceramide, which is only moderately cytotoxic, viability fell precipitously[1].
Cell Assay	Cells are seeded in 96-well plates. Drugs (including MCI826 (VX-710)) are diluted freshly into culture medium containing 1% FBS and added to wells to a total volume of 0.2 mL, thus the final concentration of FBS during treatment is 5.5%. After addition of agents, cells are incubated at 37°C for 72 or 96 hr, and cell viability is determined using cell proliferation assay kit[1].
References	[1]. Morad SA, et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol. 2013 Apr 15;85(8):1057-65.